ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2277

Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis

John Bui1, Jason Dubovsky2, Jennifer Abrams3, Sara Charmsaz4, Michelle Blake1, Joshua Beilke4, Anne-Renee van der Vuurst de Vries1, Joseph Arron5, Jonathan Graf6 and Jeffrey Bluestone7, 1Sonoma Biotherapeutics, Seattle, WA, 2Sonoma Biotherapeutics, South San Francisco, 3Sonomabio, San Francisco, CA, 4Sonoma Biotherapeutics, Seattle, 5Sonoma Biotherapeutics, San Francisco, CA, 6UCSF, San Francisco, CA, 7Sonoma Biotherapeutics, South San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: Biomarkers, immunology, rheumatoid arthritis, T Cell, Treg cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2265–2289) Rheumatoid Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers. In this study, we sought to identify direct cellular biomarkers in RA by comprehensively profiling immune subsets from whole blood.

Methods: Here, three flow cytometry panels measuring 18 markers were used to identify T cell subsets. PBMC were profiled from 30 RA subjects with varying disease severity measured by DAS28-CRP, DAS28-ESR and CDAI in addition to 23 age-, gender-, and race-matched healthy donor control subjects (HD). A two-tiered approach was applied for data analysis: Tier 1) Identify cell subsets significantly different between RA and HD and Tier 2) Correlate cell subsets identified in Tier 1 with RA clinical disease severity.

Results: The analysis revealed a significant difference (p≤0.001) between RA (12%) and HD (39%) in the frequency of an effector regulatory T cells (Treg) phenotype defined by CD4+FOXP3+CD25hiCD45RA-. Furthermore, the frequency of these cells was inversely correlated with disease severity measured by DAS28-CRP (r = -0.525, p = 0.039). Activation and proliferation markers on the Tregs in the RA subjects were similarly inversely correlated with DAS28-CRP (r= -0.53 HLA-DR, r= -0.49 CTLA-4, r= -0.52 Ki67). In contrast, the T effector cell subset phenotype data reveal significantly higher frequency (p=0.001) of CD4+CD45RA-CCR7+ central memory CD4+ T cells (Tcm) in RA (31%) compared to HD (20%). Moreover, the frequency of CD4+ Tcm was positively correlated with DAS28-ESR (r = 0.615, p = 0.037).

Conclusion: We show that, compared to healthy subjects, RA patients have significantly reduced proportion of Tregs with an effector phenotype and a higher proportion of CD4 Tcm. These phenotypic frequencies correlate with disease severity, highlighting a relationship of these immune subsets to the pathogenesis of RA. Additional characterization of these subsets will be pursued to determine their potential utility as pharmacodynamic biomarkers.


Disclosures: J. Bui: Sonoma Biotherapeutics, 3; J. Dubovsky: Sonoma Biotherapeutics, 3; J. Abrams: None; S. Charmsaz: None; M. Blake: Sonoma Biotherapeutics, 3, 11; J. Beilke: Sonoma Biotherapeutics, 3; A. van der Vuurst de Vries: None; J. Arron: Sonoma Biotherapeutics, 12,, 3, 4; J. Graf: None; J. Bluestone: Gilead, 4.

To cite this abstract in AMA style:

Bui J, Dubovsky J, Abrams J, Charmsaz S, Blake M, Beilke J, van der Vuurst de Vries A, Arron J, Graf J, Bluestone J. Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/immunophenotyping-of-peripheral-blood-mononuclear-cells-reveals-potential-cellular-biomarkers-of-disease-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunophenotyping-of-peripheral-blood-mononuclear-cells-reveals-potential-cellular-biomarkers-of-disease-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology